Company
Every investor coverage indicates participated in a round NYU raised.
Companies NYU acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Eric D. Donnenfeld | Clinical Professor of Ophthalmology | Brandon BioCatalyst portfolio |
Stories naming NYU. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Eye-drug developer Azura Ophthalmics, working from Melbourne and Tel Aviv, has assembled a seven-member scientific advisory board of ophthalmology specialists to guide clinical development of its lead candidate AZR-MD-001.